How important is understanding the tumour microenvironment in treating CLL?
Should standard chemotherapy regimens be altered in favor of small molecules? iFCG for frontline CLL
Why do charities need to keep funding research into leukemia and blood cancer in general?
Neomorphic mutations driving hematological cancers
Advancements in AML therapy at ASH 2017